Inclusion Criteria:

- Philadelphia chromosome positive or bcr-abl gene positive

- Chronic Myelogenous Leukemia (CML)

- Subjects must have primary or acquired resistance to imatinib mesylate or have
intolerance of imatinib mesylate

- Philadelphia Chromosome Positive Acute Lymphoblastic leukemia (Ph+ALL)

- Subjects must have primary or acquired resistance to chemotherapy or have intolerance
of chemotherapy

- Performance status (general conditions) specified by the Eastern Cooperative Oncology
Group: 0-2

- Men and women, ages 20 - 75

- Women of childbearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy throughout the study and for up to 3 months after
the study in such a manner that the risk of pregnancy is minimized

Exclusion Criteria:

- Subjects who are eligible and willing to undergo transplantation at pre-study

- Women who are pregnant or breastfeeding

- Uncontrolled or significant cardiovascular disease

- History of significant bleeding disorder unrelated to CML or ALL

- Adequate hepatic function

- Adequate renal function

- Medication that increase bleeding risk

- Medication that change heart rhythms

- Subjects who are compulsorily detained for legal reasons or treatment of either a
psychiatric or physical (e.g., infectious disease) illness must not be enrolled into
this study